global glp-1 market size 2025 Receptor Agonist and Strategies To 2035 GLP-1 Agonists Weight Loss Drugs

Among anti-obesity medication (AOM) users, the switch rate is just 2 percent, while type 2 diabetes (T2D) patients show a slightly higher rate at 7 percent, likely due to broader payer coverage for branded diabetes therapies

Each reflects the same underlying receptor signaling described earlier, but the specific findings and study methods differ by outcome area

ECM remodeling is a pathological hallmark of hepatic fibrogenesis in MAFLD and plays a central role in linking thyroid dysfunction to progressive liver injury (109)

People on any type of weight loss medication lost an average of 8.3kg during treatment, but regained 4.8kg within the first year and were back to their original weight within 1.7 years of stopping the drugs

Eric Topol (37:32): Well, you're showing us the way